Cantor Fitzgerald Reiterates Overweight on Intra-Cellular Therapies, Maintains $98 Price Target
Portfolio Pulse from richadhand@benzinga.com
Cantor Fitzgerald analyst Charles Duncan has reiterated an Overweight rating on Intra-Cellular Therapies (NASDAQ:ITCI) and maintained a $98 price target.
August 22, 2023 | 1:50 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Cantor Fitzgerald has reiterated an Overweight rating on Intra-Cellular Therapies and maintained a $98 price target, indicating a positive outlook for the company.
Analyst ratings and price targets can significantly influence investor sentiment and stock prices. The reiteration of an Overweight rating and a high price target by Cantor Fitzgerald suggests a positive outlook for Intra-Cellular Therapies, which could lead to an increase in its stock price in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100